Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

$CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )$

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CTC count as a prognostic marker for androgen deprivation plus orteronel or...

Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation...

Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer ( Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

COVID-19 and breast cancer: How should we treat our patients?

Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain

COVID-19 and breast cancer: How should we treat our patients? ( Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain )

PARP inhibitors in prostate cancer: Choices of tests and how to test?

Dr Kim Chi and Dr Alexander Wyatt

PARP inhibitors in prostate cancer: Choices of tests and how to test? ( Dr Kim Chi and Dr Alexander Wyatt )

ASCO 2020: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2020: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2020 prostate cancer highlights

Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl

ASCO 2020 prostate cancer highlights ( Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl )

Perioperative novel systemic immunotherapy-based approaches in urinary cancers

Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA

Perioperative novel systemic immunotherapy-based approaches in urinary cancers ( Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA )

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to...

Prof Benoit You - Hospices Civils de Lyon, Lyon, France

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy ( Prof Benoit You - Hospices Civils de Lyon, Lyon, France )

More from ecancer